+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Mini ReportOpen Access

Trailing TRAIL Resistance for Targeted Cancer Therapy

Volume 4 - Issue 1

Ngai Siew Ching* and Wong How Ming Sonia

  • Author Information Open or Close
    • Faculty of Science, University of Nottingham Malaysia Campus, Malaysia/li>

    *Corresponding author: Ngai Siew Ching, School of Biosciences, Faculty of Science, University of Nottingham Malaysia Campus, 43500 Semenyih, Selangor, Malaysia

Received: April 09, 2018;   Published: April 20, 2018

DOI: 10.26717/BJSTR.2018.04.000987

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising anti-cancer agent due to its selective killing of cancer cells, sparing the vital normal cells. Despite its great potential in cancer treatment, its clinical application has been hampered by the cancer resistance. Various strategies have been developed to overcome resistance towards TRAIL-induced apoptosis which include the combinational therapy of TRAIL with epigenetic drugs, chemotherapy drugs and the autophagy inhibitors. To heighten the therapeutic outcome, the personalized medicine based on biomarker screening could serve as a novel strategy in tailoring the combinational therapy of TRAIL and sensitizer for targeted cancer therapy in the near future.

Abbrevation: TNF: Tumour Necrosis Factor; TRAIL: Tumour Necrosis Factor Related Apoptosis-Inducing Ligand; DISC: Death Inducing Signalling Complex; FADD: Fas Associated Death Domain

Abstract| Introduction| Resistance| Sensitization of Cancer Cells Towards TRAIL-Induced Apoptosis| Conclusion and Future Prospects| References|